Lördag 21 December | 17:41:15 Europe / Stockholm

Kalender

Tid*
2025-12-03 N/A Årsstämma
2025-11-05 08:00 Bokslutskommuniké 2025
2025-08-22 07:00 Kvartalsrapport 2025-Q3
2025-05-07 07:00 Kvartalsrapport 2025-Q2
2025-01-30 07:00 Kvartalsrapport 2025-Q1
2024-12-05 - X-dag ordinarie utdelning AMBU B 0.38 DKK
2024-12-04 - Årsstämma
2024-11-05 - Bokslutskommuniké 2024
2024-08-30 - Kvartalsrapport 2024-Q3
2024-05-14 - Kvartalsrapport 2024-Q2
2024-01-30 - Kvartalsrapport 2024-Q1
2023-12-14 - X-dag ordinarie utdelning AMBU B 0.00 DKK
2023-12-13 - Årsstämma
2023-11-08 - Bokslutskommuniké 2023
2023-08-31 - Kvartalsrapport 2023-Q3
2023-05-03 - Kvartalsrapport 2023-Q2
2023-02-07 - Kvartalsrapport 2023-Q1
2022-12-15 - X-dag ordinarie utdelning AMBU B 0.00 DKK
2022-12-14 - Årsstämma
2022-11-15 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q3
2022-05-10 - Kvartalsrapport 2022-Q2
2022-02-08 - Kvartalsrapport 2022-Q1
2021-12-15 - X-dag ordinarie utdelning AMBU B 0.29 DKK
2021-12-14 - Årsstämma
2021-11-09 - Bokslutskommuniké 2021
2021-08-17 - Kvartalsrapport 2021-Q3
2021-05-12 - Kvartalsrapport 2021-Q2
2021-01-27 - Kvartalsrapport 2021-Q1
2020-12-10 - X-dag ordinarie utdelning AMBU B 0.29 DKK
2020-12-09 - Årsstämma
2020-11-11 - Bokslutskommuniké 2020
2020-08-26 - Kvartalsrapport 2020-Q3
2020-05-05 - Kvartalsrapport 2020-Q2
2020-02-04 - Kvartalsrapport 2020-Q1
2019-12-18 - X-dag ordinarie utdelning AMBU B 0.38 DKK
2019-12-17 - Årsstämma
2019-11-13 - Bokslutskommuniké 2019
2019-08-22 - Kvartalsrapport 2019-Q3
2019-05-01 - Kvartalsrapport 2019-Q2
2019-01-31 - Kvartalsrapport 2019-Q1
2018-12-13 - X-dag ordinarie utdelning AMBU B 0.40 DKK
2018-12-12 - Årsstämma
2018-11-13 - Bokslutskommuniké 2018
2018-08-23 - Kvartalsrapport 2018-Q3
2018-05-07 - Kvartalsrapport 2018-Q2
2018-01-31 - Kvartalsrapport 2018-Q1
2018-01-03 - Split AMBU B 1:5
2017-12-14 - X-dag ordinarie utdelning AMBU B 1.85 DKK
2017-12-13 - Årsstämma
2017-09-30 - Bokslutskommuniké 2017
2017-08-23 - Kvartalsrapport 2017-Q3
2017-05-02 - Kvartalsrapport 2017-Q2
2017-02-01 - Kvartalsrapport 2017-Q1
2016-12-13 - X-dag ordinarie utdelning AMBU B 1.55 DKK
2016-12-12 - Årsstämma
2016-09-30 - Bokslutskommuniké 2016
2016-08-19 - Kvartalsrapport 2016-Q3
2016-05-03 - Kvartalsrapport 2016-Q2
2016-01-29 - Kvartalsrapport 2016-Q1
2015-12-11 - X-dag ordinarie utdelning AMBU B 0.95 DKK
2015-12-10 - Årsstämma
2015-11-11 - Bokslutskommuniké 2015
2015-08-19 - Kvartalsrapport 2015-Q3
2015-05-06 - Kvartalsrapport 2015-Q2
2015-02-02 - Kvartalsrapport 2015-Q1
2014-12-23 - Split AMBU B 1:4
2014-12-18 - X-dag ordinarie utdelning AMBU B 3.75 DKK
2014-12-17 - Årsstämma
2014-11-13 - Bokslutskommuniké 2014
2014-08-20 - Kvartalsrapport 2014-Q3
2014-05-02 - Kvartalsrapport 2014-Q2
2014-02-04 - Kvartalsrapport 2014-Q1
2013-12-13 - X-dag ordinarie utdelning AMBU B 1.25 DKK
2013-12-12 - Årsstämma
2013-09-30 - Bokslutskommuniké 2013
2013-08-20 - Kvartalsrapport 2013-Q3
2013-05-02 - Kvartalsrapport 2013-Q2
2013-02-05 - Kvartalsrapport 2013-Q1
2012-12-14 - X-dag ordinarie utdelning AMBU B 3.00 DKK
2012-12-13 - Årsstämma
2012-09-30 - Bokslutskommuniké 2012
2012-08-23 - Kvartalsrapport 2012-Q3
2012-05-03 - Kvartalsrapport 2012-Q2
2012-02-09 - Kvartalsrapport 2012-Q1
2011-12-16 - X-dag ordinarie utdelning AMBU B 2.00 DKK
2011-12-15 - Årsstämma
2011-09-30 - Bokslutskommuniké 2011
2011-08-25 - Kvartalsrapport 2011-Q3
2011-05-09 - Kvartalsrapport 2011-Q2
2011-02-07 - Kvartalsrapport 2011-Q1
2010-12-17 - X-dag ordinarie utdelning AMBU B 2.50 DKK
2009-12-17 - X-dag ordinarie utdelning AMBU B 1.50 DKK
2005-03-01 - Split AMBU B 1:2
2004-02-10 - Split AMBU B 1:10

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Ambu är verksamt inom medicinteknik. Bolaget utvecklar och marknadsför diagnostisk utrustning för aktörer inom vård- och omsorg. Störst verksamhet återfinns inom utvecklingen av lösningar för endoskopi, gastroskopi och patientövervakning. Verksamhet innehas på global nivå med störst närvaro inom Europa och Nordamerika. Ambu grundades 1937 och har sitt huvudkontor i Ballerup, Danmark.
2024-04-10 21:27:09

10.4.2024 21:27:06 CEST | Ambu A/S | Inside information

Today, Ambu announces preliminary results for the first half-year of 2023/24 and adjusts its expectations for the full financial year 2023/24. As a result of solid financial performance year-to-date and expected continued momentum in revenue growth, Ambu increases its financial outlook for organic revenue growth to 10-12% (previously 7-10%) and for EBIT margin before special items to 10-12% (previously 8-10%).

In addition, the company raises its free cash flow expectations to DKK +370m (previously DKK +270m).

The raised outlook is mainly driven by better-than-expected outcomes of contract negotiations in Anaesthesia & Patient Monitoring, strong organic growth in Endoscopy Solutions and continued strengthened operational leverage. 


PRELIMINARY AND UNAUDITED FINANCIAL HIGHLIGHTS FOR Q2 2023/24

Last year’s comparative figures are stated in brackets.

  • Revenue was DKK 1,367m (DKK 1,189m), with organic revenue growth of 15.5% (4.2%). Reported growth for the quarter was 15.0% (6.0%). Year-to-date, organic growth was 14.9% (4.0%), with reported growth of 12.9% (7.8%).
  • EBIT before special items was DKK 194m (DKK 46m) and year-to-date was DKK 320m (DKK 114m). EBIT margin before special items was 14.2% (3.9%) and ended year-to-date at 12.2% (4.9%). The strengthened EBIT margin was mainly driven by organic growth in revenue and operational leverage on OPEX, although partially offset by increased investments in resources to drive organic growth. The investments in resources are expected to increase for the remaining financial year.
  • Free cash flow was DKK 128m (DKK 21m), bringing the year-to-date free cash flow to a total of DKK 263m (DKK -153m). 


REVISED OUTLOOK FOR THE FISCAL YEAR 2023/24

Driven by the development in the first half of the 2023/24 financial year, Ambu’s 2023/24 financial outlook is set as per below:

Outlook FY 2023/24

10 April 2024

  Previously

Organic revenue growth10-12%7-10%
EBIT margin before special items10-12%8-10%

In addition, Ambu’s free cash flow expectations are set for DKK +370m (previously DKK +270m), while the expectation for Endoscopy Solutions organic revenue growth is maintained at ~15%.

Ambu will publish its full Q2 and half-year 2023/24 interim results, as previously announced, on 14 May 2024.

Contacts

  • Anders Hjort, Head of Investor Relations, +45 2892 8881, anhj@ambu.com
  • Tine Bjørn Schmidt, Head of Corporate Communications, +45 2264 0697, tisc@ambu.com

About Ambu A/S

Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,600 people in Europe, North America, Latin America and Asia Pacific.

For more information, please visit Ambu.com.

Attachments